NCT03552536View on ClinicalTrials.gov

MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 7, 2018

Primary Completion Date

March 11, 2019

Study Completion Date

March 11, 2019

Conditions
HIV-1 Infection
Interventions
DRUG

MK-8583

A single oral dose of MK-8583 in capsule form

Trial Locations (1)

10117

Charite Research Organisation GmbH ( Site 0001), Berlin

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03552536 - MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002) | Biotech Hunter | Biotech Hunter